Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 165 of 667 results for diabetes

  1. Empagliflozin for treating chronic kidney disease (TA942)

    Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic kidney disease in adults.

  2. Bipolar, schizophrenia and other psychoses: annual blood glucose or HbA1c (IND159)

    This indicator covers the percentage of patients aged 18 years and over with schizophrenia, bipolar affective disorder and other psychoses who have a record of blood glucose or HbA1c in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM130

  3. Coeliac disease (QS134)

    This quality standard covers recognising, assessing and managing coeliac disease in adults, young people and children. It describes high-quality care in priority areas for improvement.

  4. Guidance on the use of coronary artery stents (TA71)

    Evidence-based recommendations on using coronary artery stents in adults.

  5. Forward view - our priority topics

    Our forward view highlights the areas we will prioritise in the coming year.

  6. Bedwetting in under 19s (CG111)

    This guideline covers assessing and treating bedwetting in people aged under 19. It aims to reduce bedwetting and the distress this causes by explaining what to ask in an assessment, what advice to provide, and which treatments are effective.

  7. Overweight and obesity management (QS212)

    This quality standard covers prevention, behavioural management, assessment, and treatment of overweight, obesity and central adiposity in children and young people aged over 2 years, and adults. This includes those with established comorbidities, and those with risk factors for other medical conditions. It describes high-quality care in priority areas for improvement.

  8. Dapagliflozin for treating chronic kidney disease (TA1075)

    Evidence-based recommendations on dapagliflozin for treating chronic kidney disease in adults.

  9. In consultation

    See a complete list of indicators currently in consultation. Our indicators measure outcomes that reflect the quality of care or processes.

  10. Bipolar disorder in adults (QS95)

    This quality standard covers recognising, assessing and managing bipolar disorder in adults (aged 18 and over) in primary and secondary care. It describes high-quality care in priority areas for improvement.

  11. Stable angina: management (CG126)

    This guideline covers managing stable angina in people aged 18 and over. It outlines the importance of addressing the person’s concerns about stable angina and the roles of medical therapy and revascularisation.

  12. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]

    In development Reference number: GID-TA11414 Expected publication date:  10 June 2026

  13. Long-term outcomes of bariatric surgery on people with type 2 diabetes: What is the long-term effect of bariatric surgery on diabetes-related complications and quality of life in people with type 2 diabetes compared with optimal medical treatment?

    type 2 diabetes: What is the long-term effect of bariatric surgery on diabetes-related complications and quality of life in...

  14. Management of type 3c diabetes:- What is the most clinically effective and cost-effective insulin regimen to minimise hypo- and hyperglycaemia for type 3c diabetes secondary to pancreatitis?

    type 3c diabetes:- What is the most clinically effective and cost-effective insulin regimen to minimise hypo- and hyperglycaemia for...

  15. Continuous glucose monitoring in children and young people with type 2 diabetes: What is the effectiveness and cost effectiveness of continuous glucose monitoring devices in children and young people with type 2 diabetes?

    Continuous glucose monitoring in children and young people with type 2 diabetes: What is the effectiveness and cost effectiveness of...